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Abstract  
BACKGROUND: The role of the CARD15 gene 3020insC frameshift mutation in the pathogenesis 
of inflammatory bowel diseases (IBD) investigated without a definitive conclusion. The incidence of 
this mutation in Turkish patients with Crohn’s disease is not known.  
OBJECTIVE: We investigated whether the CARD15/NOD2 3020insC frameshift mutation is a risk 
factor for patients with inflammatory bowel disease in Black Sea Region population in Turkey.  
METHODS: We studied 3020insC mutation of CARD15/NOD2 gene by allele-specific multiplex 
PCR in 69 patients with IBD (18 Crohn’s disease [CD] and 51 ulcerative colitis [UC]) and 101 
ethnically matched healthy controls.  
RESULTS: CARD15/NOD2 3020insC frameshift mutation was positive in 7/18 (38.8 %), 13/51 
(25.5 %), and 4/101 (4 %) of CD, UC, and healthy control groups, respectively. None of the controls 
or patients with Crohn’s disease and ulcerative colitis was homozygous for this mutations.  
CONCLUSION: This study is to investigate a relation between CARD15/NOD2 3020insC frameshift 
mutation and in patients with IBD in the Turkish Population. C-insertion frameshift mutation is a 
major contributor to the susceptibility to both CD and UC, but it is not specific to patients with CD in 
Turkish population. 
 
 
 
 
 
 
Introduction 
Crohn’s disease (CD) and ulcerative colitis 
(UC) are two main forms of inflammatory bowel 
diseases (IBD) characterized by chronic inflammation 
of the digestive tract sometimes associated with an 
extra digestive inflammation [1]. The incidence of 
these diseases is higher in developed countries. The 
origin, etiology, and pathogenesis of IBD have not 
been fully understood [1, 2]. In recent years, certain 
genes were identified in the pericentromeric region of 
human chromosome 16 (locus IBD1) that increase the 
susceptibility to inflammatory bowel diseases, both 
chronic UC and CD. However, the candidate genes 
did not show a definitive association with this 
pathology [1, 3]. Recent articles proposed a gene on 
chromosome 16q12, known as CARD15 (NOD2) is 
possibly responsible for CD [4-8]. Identified nucleotide 
oligomerisation domain (NOD2) as the IBD gene and 
recently, the nomenclature of NOD2 has been 
changed to caspase activating recruitment domain 
(CARD15). CARD15/NOD2 has a role in inflammatory 
response to bacterial triggers, especially 
lipopolysaccharides (LPS), and is expressed 
exclusively in monocytes and it has structural 
homology with R protein which is a class of plant 
disease resistance gene product [8]. CARD15/NOD2 
comprises an amino terminal effector domain, a 
nucleotide-binding domain and leucine-rich repeats 
(RRs) and regulates apoptosis and/or nuclear factor 
(NF)-B activation [9]. The C-insertion mutation at 
nucleotide 3020 (3020insC) in the LRR region results 
in a frameshift in the 10
th
 LRR followed by a 
premature stop codon [10]. This truncation mutation is 
responsible for the inability to activate nuclear factor 
(NF)-B in response to bacterial LPS [10, 11]. 
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The frequency of CARD15/NOD2 3020insC 
frameshift mutation and relationships with IBD in 
various populations was investigated by researchers 
and the genetic heterogeneity of CD in different 
populations was established. Here we studied this 
frameshift mutation in 69 Turkish patients with IBD (18 
CD, 51UC) and 101 healthy control subjects, to 
identifiy the susceptible gene for Turkish population.  
 
Materials and Methods 
Study patients and control subjects  
We studied 69 unrelated patients 18 CD and 
51 UC. The study also included 101 healthy control 
subjects. These control subjects were without a 
personal or family history of inflammatory bowel 
disease. Blood samples were obtained from patients 
(n = 69) at Kocaeli University Hospital and Karadeniz 
Technical University Farabi Hospital in Black Sea 
Region of Turkey. Blood samples were obtained from 
healthy control subjects (n = 101) in same region.The 
diagnosis of either ulcerative colitis or CD was 
confirmed by clinical, radiological, endoscopic and 
histological examination in accordance with Vienna 
classification (Gasche et al., 2000). Suspicious cases 
were excluded from the study.  
  
DNA extraction and 3020insC frameshift 
mutation analysis 
Blood samples were drawn from cases and 
controls in the fasting state and collected in EDTA-
tubes (Vacutaine, Becton Dickinson, Meylon, France). 
DNA was extracted with salting out method [12] from 
peripheral blood leukocytes using the Pure gene 
TM
 
DNA extraction kit (GENTRA, Minneapolis, USA). 
DNA concentrations were measured 
spectrophotometrically at 260 nm and stored at –
70
o
C. All tests were subsequently performed within 3 
weeks of collection.  
Table 1: CARD15/NOD2 3020insC Frameshift Mutation Allele-
Specific PCR Conditions. 
Stock 
Concentrations 
Final 
Conc. 
Volume 
(25 l) 
Primer Sequences (5' → 3') 
10XPCR buffer 1X 5,0 l  
25 mM MgCl2 2.5 mM 1.5 l   
25 mM dNTP Mix 0.2 mM 1.5 l   
Control-F(100 uM)   .25uM 1.5 l CTGAGCCTTTGTTGATGAGC 
Control-R (100 uM) 1 uM 1.5 l TCTTCAACCACATCCCCATT 
Allele-specific(wt)-F 
(100 uM) 
1 uM 1.5l CAGAAGCCCTCCTGCAGGCCCT 
Allele-
specific(insC)-R(100 
uM) 
0.25 uM 1.5 l CGCGTGTCATTCCTTTCATGGGGC 
Patient’s DNA 30ng/l 2 l  
Taq  Pol (5U/ul) 0.03U/l 1.0 l  
Sterile ddH2O   13.0 l  
 
The CARD15/NOD2 3020insC frameshift 
mutation was genotyped by using allele-specific 
multiplex polymerase chain reaction (PCR), in MJ 
PTC-100
TM
 Thermocycler (MJ Research, Inc. 
USA).The primers required for this method were 
purchased from Promega.  PCR conditions were as 
follows (Table 1): an initial denaturation for 2 min at 94 
o
C, then, 35 cycle at 94 
o
C for 30 s, at 60 
o
C for 30 s, 
at 72 
o
C for 1min and final extension at 72 
o
C for 10 
min (Ogura et al., 2001). The PCR products were 
detected by agarose gel electropheresis (at 70V, 55 A 
for 1h) on 2% agarose gel containing ethidium bromide 
and the fluorescent intensity of each band was 
evaluated with a UV transilluminator. The three 
genotypes were defined as follows; 300 bp, normal 
homozygous; 200 bp and 300 bp (two band in 
electropheresis), heterozygous; and only 200 bp, 
mutant homozygous (Figure 1).  
 
Figure 1: Electrophoresis pattern of CARD15/NOD2 Genes 
3020insC mutation (1-4 Normal. 200 bp and 5, 6 Heterozygous  
200/300 bp). 
 
Statistical Methods 
 In this study, the statistical analyses were 
made with the Graphpad Prism 6.02 software. In the 
evaluation of the data, in addition to the descriptive 
statistical methods (mean, standard deviation), the χ
2
 
test was used in the comparison of the patient and 
control groups and the Fisher reality test was used in 
the comparisons of the qualitative data. The 
significance level of P = 0.05 was taken as basis in 
the evaluation of the results. In the calculation of the 
genotypes and allele frequencies, Hardy-Weinberg 
equality was taken as basis. 
 
Results  
The distribution of CARD15/NOD2 3020insC 
frameshift mutation in the two groups of patients and 
control subjects is shown in Table 2.  
Table 2: CARD/15NOD2 3020insC frameshift mutation in IBD 
(UC, CD) and healthy controls in Turkish population. 
Patients Wild type  Heterozygote  Homozygote  P value 
UC ( n =51 ) 38 (74.6 % ) 13 ( 25.4 %) 0  0.0001 
CD ( n =18 ) 11 ( 61.1 % ) 7 ( 38.9 % ) 0  0.0002 
Total IBD (n = 69 ) 49 ( 71 % ) 20 ( 29 % ) 0 0.0001 
Controls ( n =101) 97 ( 96 % )   4 (4 % ) 0 0.0001 
 
According to allele-specific multiplex PCR 
results, the frequencyes of this frameshift mutation in 
Turkish patients were 38.8 % (7 of 18), 25.4 % (13 of 
51) and 4 % (4 of 101) in CD, UC and healthy 
subjects, respectively. None of the controls or patients 
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with CD and ulcerative colitis was homozygous for 
these mutations. Significant differences were found in 
the genotype and allele frequencies of the C-insertion 
mutation of CARD15/NOD2 gene among patients with 
IBD (Crohn’s disease and ulcerative colitis) and 
healthy controls (P < 0.05). In this study, prevalence 
of C-insertion mutation of CARD15/NOD2 gene was 
found to be higher in patients with CD than UC. 
However, the difference was not significant (P > 0.05). 
 
 Discussion 
CD and UC are classified as chronic 
idiopathic inflammatory bowel diseases.  The 
incidence of these diseases is higher in developed 
countries such as USA, Japan and East European 
countries and it has increased about twofold in these 
countries from 1970s to date [13]. Although its 
etiology and pathogenesis have not been fully 
understood, result of epidemiological and genetic 
linkage studies have suggested that IBD is 
predisposed by certain genetic and environmental 
factors [14]. The origin of CD is still an enigma in 
current medicine. In this study, we investigated the 
association between 3020insC variants and IBD 
disease using healthy controls. Genomic analyses 
and statistical association revealed that the mutation 
in the region is associated with CD and ulcerative 
colitis among the Black Sea Region population in 
Turkey. The previous literature has indicated that the 
rare CARD15/NOD2 3020insC is the risk factor for the 
CD among different populations [15, 16].  Among the 
Japanese population however, patients with the CD 
did not carry the mutants [17]. The frequency of the 
mutants in the African American patients of CD was 
found to be lower in comparison to the patients who 
are Caucasian Americans [18]. The literature indicates 
that the frequency of mutation varies in different ethnic 
populations. Therefore, association studies on the 
frequency of mutation in patients with the CD should 
target each population individually before any clinical 
implication [19]. This study is to our knowledge the 
first attempt to target the IBD patients in the Black Sea 
population of Turkey and has potential to be applied in 
the clinical diagnosis.   The difference of the mutation 
frequency in various populations is an important 
research question.  Hence, intensive research has 
been conducted to tackle the patterns of mutation 
among various ethnic groups in different continents. 
The incidence of 3020insC mutation of 
CARD15/NOD2 in European populations who carry 
the CD was found to be about 12% [20-24]. The more 
detailed analyses among European population 
revealed that the frequency of the mutation was 16% 
among Germans [18, 25], 11.6% among Italians [21], 
9.4% among British [26, 27] and 10.9% among Dutch 
[23, 24]. In the North America, the reported results 
indicated that the frequency of the mutation was 8.4% 
for Caucasian Americans [25-28], 7.8-8.4% for Jewish 
[29] and 1.3-3.7% among Chinese [30-32]. The 
prevalence of 3020insC, a frameshift mutation of 
CARD15/NOD2 gene among the members of Jewish 
population in various regions who carry CD was found 
to be around 7.3% whereas the same mutation was 
found to be 8.4% among the members of non-Jewish 
population [23]. The frequency of the mutation among 
the Jews who have CD was 8.7% whereas the 
frequency was found to be 3.2% in control group. 
However, the occurrence of the mutation among non-
Jewish populations who had CD was 4.3% and that of 
control group was about 1.6% [28]. The elevated 
number of Crohn alleles could be linked to the effect 
of prevalence of the mutants [33, 34]. In the present 
study, we found that the frequency of the 3020insC 
mutant was about 25.4%, which was found to be 
higher than European populations [30]. Our results 
are in agreement with the previous literature in which 
the prevalence of a mutation of 3020insC was found 
to be higher among Caucasians who have CD in 
comparison with European population. This is 
particularly important since the region we studied is 
very close to Caucasia. The previous studies have 
rarely described the mutation in the context of UC 
[35]. In CD, same mutation 3020insC was studied by 
some of the groups West of Turkey but their results 
suggested lower frequnces than in our results [36]. 
In this study, we found that in addition to CD, 
the frequency of the mutation is very high among the 
patients of UC. The 3020insC mutation of CARD15 
gene has been suggested useful in clinic diagnosis of 
CD and UC both of which are IBD. However, we have 
found the prevalence of mutation to be 25.4% among 
patients of CD and %38.8 among those who are UC.. 
Based on this result we conclude that this particular 
mutation may not be suitable as a diagnostic marker 
to differentiate between the two IBD types at least for 
the Black Sea region. Investigation of a similar pattern 
among other populations will be an interesting 
research venue. Moreover, the genetic heterogeneity 
of the Anatolian population is not well understood due 
to paucity of research and more in-depth analyses of 
linkage between those mutations and IBD has 
potential for clinic applications.  
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